HAVE YOU READ THE
CHANTIX WARNINGS?
Are you or a loved one trying to quit Smoking?
Are you or your loved one using Chantix to help stop smoking?
Do you know that the FDA (Food and Drug Administration) made an announcement on 16 June 2011 reflecting their concerns about the safety of using Chantix.
Do you know that a report released by the Canadian Medical Association Journal, using over 8000 participants, found that the risk of developing or worsening existing cardiovascular disorders in specific population groups, increased by 72% for patients using Chantix (Champix in Canada)?
Do you know that from the year after Chantix was first released, there have been many reports of the dangers associated with the use of this drug?
Are you, or a loved one suffering, possibly because of Chantix?
Are you, or a loved one, suffering with ill health, specifically cardiovascular disorders, subsequent to a course of Chantix?
If you feel you may be eligible to claim and receive a settlement of money compensation due to damage that may have been caused by Chantix, contact me, for a free case review.
Chantix Warnings
Chantix was approved for use by the FDA in 2006, after an abbreviated review period, based on the results of the clinical trials presented by the manufacturers, Pfizer, and because it allegedly had no harmful side-effects.
At that point Pfizer did concede that the product had not been tested on pregnant or breast feeding mothers, or on persons under the age of 18, and the labelling reflected this caveat.
After release in May 2006, Chantix (Varenicline) next made the news in September 2007 when the use of this drug was implicated in the death of musician Carter Albrecht.
Various reports, including the banning of Chantix usage by pilots and air traffic controllers, increased susceptibility to drowsiness and mood swings, depression, and suicidal tendencies caused the FDA to insist on a modification to the Chantix labelling. The FDA's strongest safety warning, a Black Box warning, was the result, as of July 2009.
New developments in recent research have prompted the FDA to inform Medical Practitioners and Chantix users that the use of Chantix may contribute to cardiovascular disease. The manufacturers have been requested to perform full clinical trials, and to submit the findings to the FDA.
Update: 22 July 2011
Chantix (varenicline) Label update approved by FDA
The FDA (Food and Drug Administration) have given their approval to a revised Chantix (varenicline) label. The revised label now includes information about the effectiveness and safety of Chantix (varenicline) for persons with cardiovascular disease and chronic obstructive pulmonary disease. Now also on the label are alternative recommendations to smokers on selecting a stop smoking date.
Mr Leeds
Mr Mark J Leeds is an expert Civil Trial Lawyer, with more than 30 years exclusive experience of Personal Injury Claims, and over 100 jury verdicts.
FREE CONSULTATION!
